Instead of testing drugs on mice and hoping they work in humans, CellType builds a digital twin of human biology and tests drugs on that first.

CellType's Virtual Human platform uses the Cell2Sentence foundation model to construct a comprehensive computational representation of human biology at single-cell resolution. By converting gene expression profiles into LLM-compatible token sequences, the model learns cellular states, tissue microenvironments, and drug-cell interaction dynamics from massive single-cell RNA-seq datasets. When a candidate compound is introduced virtually, the system predicts downstream transcriptomic changes across multiple cell types simultaneously, flagging potential efficacy signals in target tissues and toxicity risks in off-target organs. This whole-system approach addresses the fundamental limitation of traditional preclinical models—species-specific biology—by grounding every prediction in actual human data. The platform has demonstrated validated predictions of novel drug hits in immuno-oncology, with results confirmed through in vitro and ex vivo experiments. Pharma partners use the platform to de-risk pipeline decisions before committing to expensive animal studies and Phase I trials.

It's like crash-testing a car in a hyper-realistic video game before ever bending real metal—except the car is a drug and the game is a perfect simulation of your body.

CellType's AI agents act like tireless PhD researchers that read every paper, analyze every dataset, and propose the best drug targets—all before your morning coffee.

CellType's celltype-cli orchestrates autonomous research agents powered by Claude that execute end-to-end target discovery workflows without manual intervention. An agent receives a high-level therapeutic hypothesis (e.g., "find novel immunotherapy targets in triple-negative breast cancer"), then autonomously queries DepMap dependency screens, PRISM drug sensitivity data, L1000 perturbation signatures, and proteomic datasets to identify genes essential for tumor survival but dispensable in normal tissues. Simultaneously, the agent mines PubMed, ChEMBL, and UniProt via API to assess druggability, existing IP landscape, and clinical precedent. It performs pathway enrichment analysis, builds interaction networks, and ranks candidates using a multi-criteria scoring framework that balances novelty, tractability, and safety. The entire pipeline—from hypothesis to prioritized target list with supporting evidence—runs in hours rather than the weeks or months typical of manual bioinformatics. Human scientists review the agent's reasoning chain and evidence at each decision node, maintaining scientific rigor while dramatically accelerating throughput. This approach has enabled CellType's pharma partners to populate early-stage pipelines with higher-confidence targets at unprecedented speed.

It's like having a research assistant who has memorized every biology paper ever written, can run every analysis tool simultaneously, and never needs sleep—except it actually exists and works before lunch.

CellType figures out which patients a drug will actually work for before the trial even starts, so pharma companies stop wasting billions testing drugs on the wrong people.

CellType's virtual clinical trial capability leverages Cell2Sentence to model patient heterogeneity at single-cell resolution, creating in silico patient cohorts that reflect the biological diversity of real-world populations. By training on large-scale single-cell atlases spanning healthy and diseased tissues across diverse demographics, the model learns how genetic background, disease subtype, and microenvironment composition influence drug response. When a pharma partner inputs a candidate compound and target indication, the platform simulates treatment across thousands of virtual patients, predicting responders vs. non-responders based on transcriptomic signatures, pathway activation states, and immune contexture. The system outputs recommended biomarker-driven inclusion/exclusion criteria, optimal dosing strategies for different patient subgroups, and predicted effect sizes—enabling sponsors to design smaller, more targeted trials with higher probability of success. This addresses one of the most expensive failure modes in drug development: Phase II and III trials that fail not because the drug doesn't work, but because the trial enrolled the wrong patient population. By front-loading patient stratification computationally, CellType helps partners avoid costly late-stage failures and accelerate time-to-approval for precision therapies.

It's like a dating app for drugs and patients—instead of hoping for a random match, the AI figures out exactly who's compatible before anyone commits to a very expensive first date.